ライフサイエンスコーパス: intravenous infusion

1 injection) and dexamethasone (20 mg oral or intravenous infusion).

2 hcare professional or self-administered) via intravenous infusion.

3 an acceptable safety profile after a single intravenous infusion.

4 re capable of homing back to the marrow post-intravenous infusion.

5 ry application of adenosine against standard intravenous infusion.

6 dose of AMPH (0.1 mg/kg) was administered by intravenous infusion.

7 nd gave a stable aqueous system suitable for intravenous infusion.

8 tion by either intramuscular autoinjector or intravenous infusion.

9 mens including 750-1350mg orally, or a 600mg intravenous infusion.

10 administered in 28-day cycles by continuous intravenous infusion.

11 etermined with the use of a [1-(13)C]leucine intravenous infusion.

12 ns including 750-1350 mg orally, or a 600-mg intravenous infusion.

13 o system-level resilience when administering intravenous infusions.

14 ong preference or if difficulties occur with intravenous infusions.

15 essure (MAP) and heart rate 24 h/day and for intravenous infusions.

16 thy incompletely attenuated by synthetic GAA intravenous infusions.

17 practices and their effects on the safety of intravenous infusions.

18 g/m(2) per day on days 2-6), and idarubicin (intravenous infusion 10 mg/m(2) per day on days 2-4 in u

19 ) yields identical FFR results compared with intravenous infusion (140 mug/kg per minute), while requ

20 30 mg/m(2) per day on days 2-6), cytarabine (intravenous infusion 2000 mg/m(2) per day on days 2-6),

21 ay subcutaneously on days 1-5), fludarabine (intravenous infusion 30 mg/m(2) per day on days 2-6), cy

22 or 1000 mg (n = 7) dosing arms of rituximab intravenous infusions (500 or 1000 mg), given at study d

23 Rats anesthetized with isoflurane were given intravenous infusions (9 mL/kg over 1 min) of either 20%

24 osertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week or be

25 ods study of errors and policy deviations in intravenous infusion administration across 16 English ho

26 d anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, an

27 posal in rats, pigs and dogs during constant intravenous infusion and euglycemic clamp conditions.

28 raised plasma fibrinogen levels in mice via intravenous infusion and induced thrombosis by ferric ch

29 tes and nitrates [NOx]) after (15)N-arginine intravenous infusion and on asymmetric dimethylarginine

30 midazolam were independently administered by intravenous infusion and plasma and brain concentrations

31 s are trapped in the lungs immediately after intravenous infusion and their survival time in the host

32 treatment and 11.1% that of daily continuous intravenous infusions and oral valganciclovir compared w

33 mit physiological insight, e.g. the need for intravenous infusions and restriction to short-term stud

34 es have been initiated, including continuous intravenous infusions and subcutaneous IL-15 administrat

35 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or i

36 ), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicat

37 ost-partum haemorrhage, needs refrigeration, intravenous infusion, and skilled providers for optimum

38 which is currently explored by a continuous intravenous infusion approach.

39 Cetuximab was given as a weekly intravenous infusion at 250 mg/m(2) after an initial loa

40 Patients received romidepsin as an intravenous infusion at a dose of 14 mg/m(2) on days 1,

41 cycles of gemcitabine (1000 mg/m(2), 30 min intravenous infusion, at days 1, 8, and 15) and capecita

42 5% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion d

43 practice are common in the administration of intravenous infusions, but not all result in negative co

44 y by transgenic overexpression or acutely by intravenous infusion caused hypophosphatemia, phosphatur

45 Twelve biweekly intravenous infusions containing either pegloticase 8 mg

46 ects, 250 mug/M) or placebo (66 subjects) by intravenous infusion daily for 14 days.

47 blocking agent be administered by continuous intravenous infusion early in the course of acute respir

48 doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks.

49 .6, 0.9, or 1.2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25

50 Avelumab was given as a 1-h intravenous infusion every 2 weeks.

51 cetaxel was given at a dose of 75 mg/m(2) by intravenous infusion every 3 weeks for up to six cycles.

52 mg/kg or 3.4 mg/kg belantamab mafodotin via intravenous infusion every 3 weeks on day 1 of each cycl

53 igned to receive either volasertib 300 mg by intravenous infusion every 3 weeks or an investigator's

54 mg/m(2) lurbinectedin administered as a 1-h intravenous infusion every 3 weeks until disease progres

55 LE trial and received patisiran 0.3 mg/kg by intravenous infusion every 3 weeks with plans to continu

56 domly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all pati

57 etirinotecan pegol (145 mg/m(2) as a 90-min intravenous infusion every 3 weeks) or single-drug treat

58 reated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks.

59 lacebo; all study drugs were administered by intravenous infusion every 3 weeks.

60 300 mg twice daily and durvalumab 1.5 g via intravenous infusion every 4 weeks until disease progres

61 n every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens

62 mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by

63 lus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h) or best available therap

64 in appearance to bimagrumab, administered as intravenous infusions every 4 weeks for at least 48 week

65 expression received avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed dise

66 isotopic labeling with 1-(13) C(1) -acetate intravenous infusion, followed by measurement of labeled

67 se of 20 mug/kg/d administered by continuous intravenous infusion for 10 days resulted in a massive (

68 monotherapy was administered via continuous intravenous infusion for 28 days then tapered to daily i

69 ion administered over 5-20 min or continuous intravenous infusion for 6-96 h on day 1 of every 21-day

70 limumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four d

71 f approximately 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in p

72 s: 1) glucose gavage and 2) hyperinsulinemic intravenous infusion, for studies in either beta-cell sp

73 (1:1) to receive either infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and aga

74 , 252 patients were randomly assigned to the intravenous infusion group and 248 to the fixed-dose com

75 ent was reported in 25 (10%) patients in the intravenous infusion group and 26 (10%) patients in the

76 se event that led to death (urosepsis in the intravenous infusion group and acute myocardial infarcti

77 neutropenia (34 [13%] of 252 patients in the intravenous infusion group vs 35 [14%] of 248 patients i

78 Zoledronic acid given by intravenous infusion has been widely used, but places a

79 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM

80 Intravenous infusion in AKO rats of human amylin, or com

81 Intravenous infusion in mice resulted in virus replicati

82 es transgene products in cancer tissue after intravenous infusion, in a dose-related fashion.

83 The TERLI group received terlipressin by intravenous infusion, initially 3 mg/24 hours, progressi

84 vation that IL-15 administered by continuous intravenous infusion is able to induce markedly greater

85 Terlipressin given by continuous intravenous infusion is better tolerated than intravenou

86 PTRA with elamipretide (0.05 mg/kg per hour intravenous infusion, n=6) or placebo (n=8).

87 Intravenous infusion narcotics (fentanyl, morphine, or h

88 Simultaneously, a continuous intravenous infusion of (1)(3)C-leucine and (2)H(5)-phen

89 y candidates, tumor size > 2 cm) received an intravenous infusion of (18)F-fluoropaclitaxel and then

90 In contrast, intravenous infusion of (89)Zr-BVDFO and subsequent BBB

91 is the first human study to demonstrate that intravenous infusion of 0.9% saline results in reduction

92 SAP consisted of single-shot, intravenous infusion of 1.5 g of cefuroxime, a commonly

93 Patients were randomized to receive an intravenous infusion of 1.5mug/min of CGRP or placebo (i

94 compared the safety and efficacy of a single intravenous infusion of 1500 mg of dalbavancin to the 2-

95 ation, rats were pretreated with either NAc (intravenous infusion of 50 mg/kg/h) or MK-801 (0.16 mg/k

96 nd 6, stratified by study site) to either an intravenous infusion of 500 mL of crystalloid solution o

97 re randomly assigned (2:1) to receive either intravenous infusion of 600 mg of ocrelizumab (two 300 m

98 Patients received an intravenous infusion of 7.5 mg/kg MABp1 or placebo given

99 es after drug injection, animals received an intravenous infusion of [1,6-(13)C2]glucose for 8 min to

100 asting, eight healthy volunteers received an intravenous infusion of [6,6-(2)H(2)]-glucose.

101 Intravenous infusion of a nitric oxide synthase inhibito

102 e conducted two separate protocols utilizing intravenous infusion of a nitric oxide synthase inhibito

103 althy participants (Cohort A, n = 25) during intravenous infusion of a subanesthetic dose of ketamine

104 Intravenous infusion of Ab1485 protected macaques from a

105 In patients with SMA1, a single intravenous infusion of adeno-associated viral vector co

106 c), and 2 FFR measurements during continuous intravenous infusion of adenosine (140 mug/kg per minute

107 Intracoronary saline given on top of an intravenous infusion of adenosine did not further increa

108 escalation of treatment in such cases using intravenous infusion of adrenaline which has been adopte

109 A single intravenous infusion of allogeneic, bone marrow-derived

110 optimal medical treatment were randomized to intravenous infusion of allogenic UC-MSCs (Cellistem, Ce

111 erate disease in 6 adult males who underwent intravenous infusion of an adeno-associated viral (AAV)

112 lysis to compare prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams in

113 The intravenous infusion of apolipoprotein E4 exacerbated th

114 Intravenous infusion of argatroban, a direct thrombin in

115 ited by 44% in LS; however, the simultaneous intravenous infusion of ascorbic acid or apocynin acutel

116 Participants received intravenous infusion of autologous bone-marrow-derived m

117 ulfan and fludarabine, patients received one intravenous infusion of autologous CD34+ cells genetical

118 m(2)] daily for 5 days, followed by a single intravenous infusion of autologous TILs and high-dose in

119 Intravenous infusion of bezlotoxumab at a 10 mg/kg dosag

120 infusion of candesartan (4.2 mug kg(-1) ) or intravenous infusion of CAP (20 mg kg(-1) ).

121 exercise, acute normobaric hypoxia, and the intravenous infusion of catecholamines, or absent/decrea

122 Intravenous infusion of CD19-targeted nTregs into SCID-B

123 Intravenous infusion of CIK cells delayed autologous tum

124 tion with [(11)C]CUMI-101 after receiving an intravenous infusion of citalopram 10 mg or placebo in a

125 difference in DA signaling is exaggerated by intravenous infusion of cocaine.

126 uglycemic clamps with a physiologic low-dose intravenous infusion of cortisol to reproduce levels fou

127 C-verapamil (30-72 MBq/kg) before and during intravenous infusion of CsA (12 or 24 mg/kg/h, n = 2 eac

128 ned dose of oral decitabine on day -3, a 1-h intravenous infusion of decitabine 20 mg/m(2) on day 1,

129 Following intravenous infusion of either 0.9% (ISO) or 3.0% (HYPER

130 ls of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (.

131 c levels of lithium or valproate received an intravenous infusion of either ketamine hydrochloride (0

132 Specifically, intravenous infusion of either polystyrene or biodegrada

133 acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15

134 stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg p

135 In study A, subjects received an intravenous infusion of ex9-39 or saline plus an oral gl

136 (days 9 and 10) without and with a high-dose intravenous infusion of exendin [9-39].

137 on imaging through the imaging window during intravenous infusion of fluorescently labeled low and hi

138 s, and 141 patients to receive 1000 mg/m2 of intravenous infusion of gemcitabine once a week for 3 of

139 A short (30-min) intravenous infusion of GLP-2 resulted in a marked incre

140 ients undergoing colorectal surgery received intravenous infusion of glucose with amino acids.

141 under baseline conditions (n = 4) and during intravenous infusion of high-dose erlotinib (10 mg/kg/h,

142 Intravenous infusion of HYPER saline increased plasma os

143 We examined if intravenous infusion of hyperosmotic saline affects skin

144 First, acute intravenous infusion of hypertonic NaCl or AngII produce

145 tomy for esophageal adenocarcinoma) received intravenous infusion of IdU (200 mg/m(2) body surface ar

146 ral nervous uptake of the IN 210 IU dose via intravenous infusion of ins-asp at a dose of 0.12 IU/kg/

147 After 60 min, intravenous infusion of insulin (15 mU kg-1 min-1), but

148 is hypothesis, a GABA deficit was induced by intravenous infusion of iomazenil (IOM; 3.7 mug/kg), an

149 ts were randomized 1:1:1 to receive a single intravenous infusion of KB001, 3 mg/kg (n=13) or 10 mg/k

150 ive Battery (MCCB) before and after a single intravenous infusion of ketamine (0.5 mg/kg) or midazola

151 ere randomly assigned to receive a 40-minute intravenous infusion of ketamine (0.5 mg/kg) or midazola

152 le (MADRS) score of >/= 22 received a single intravenous infusion of ketamine (0.5 mg/kg).

153 nderwent MRI at baseline then 24 h following intravenous infusion of ketamine (0.5 mg/kg).

154 east an initial partial response to a single intravenous infusion of ketamine 0.5 mg/kg were randomiz

155 order patients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg

156 Intravenous infusion of ketamine hydrochloride (0.5 mg/k

157 double-blind conditions to receive a single intravenous infusion of ketamine or midazolam in a 2:1 r

158 ore symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up

159 ptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting u

160 ealthy young male volunteers underwent a 7-h intravenous infusion of l-[ring-(2)H5]phenylalanine on t

161 The first study consisted of a 5-h intravenous infusion of l-carnitine while circulating in

162 In vivo: A single intravenous infusion of lipid-free apoA-I (8 mg/kg) admi

163 ed Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1) h(-1)), De

164 C57BL/6 mice received an intravenous infusion of MBs and either "naked" luciferas

165 In phase 1, patients received an intravenous infusion of melflufen at 15 mg, 25 mg, 40 mg

166 The role of an intravenous infusion of Mg alone in facilitating electri

167 mia were not observed in rhesus monkeys when intravenous infusion of MK-3682 was completed after AMIO

168 C]raclopride displacement) in response to an intravenous infusion of morphine, and its relationship w

169 placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextros

170 ly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555

171 Intravenous infusion of Ngb-H64Q-CCC restored respiratio

172 continuous feeding on two occasions: during intravenous infusion of niacin (2.8 mg/min) and saline.

173 nts were randomly assigned 2:1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimuma

174 response system) patients 2:1 to receive an intravenous infusion of nivolumab 3 mg/kg every 2 weeks

175 d ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cispl

176 , 34 healthy men received a 6-h double-blind intravenous infusion of omecamtiv mecarbil or placebo on

177 use of interactive responsive technology to intravenous infusion of pamrevlumab 30 mg/kg or placebo

178 response system, to standard care plus 48-h intravenous infusion of placebo (n=62) or relaxin 10 mic

179 e randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, e

180 ulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2

181 tivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m(2) followed by a 3-h

182 Intravenous infusion of protein/peptide Ags linked to sy

183 rticipants with magnetoencephalography after intravenous infusion of psilocybin--prodrug of the nonse

184 one for 1 month (control) or to add a single intravenous infusion of rituximab (375 mg/m(2); interven

185 revious randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in p

186 rticipants were randomized to receive a 6-hr intravenous infusion of saline (control), an intermediat

187 g healthy males: (1) NVC was assessed during intravenous infusion of saline (placebo) and the non-sel

188 ter presentation to receive either a 48-hour intravenous infusion of serelaxin (30 mug per kilogram o

189 s in mean arterial pressure (MAP) induced by intravenous infusion of sodium nitroprusside (SNP) and p

190 th untreated or relapsed BPDCN to receive an intravenous infusion of tagraxofusp at a dose of 7 mug o

191 can and a second scan either with concurrent intravenous infusion of the ABCB1 inhibitor tariquidar (

192 oom temperature (22 degrees C) for 4 h or by intravenous infusion of the alpha-adrenergic receptor an

193 vity in 33 individuals who received a single intravenous infusion of the antibody.

194 Intravenous infusion of the clinical-stage POL5551 analo

195 gether with duodenal nutrition perfusion and intravenous infusion of the glucagon-like peptide 1 (GLP

196 que monkey under control conditions or after intravenous infusion of the NET inhibitor desipramine (D

197 uted tomography (SPECT) images obtained with intravenous infusion of the radioactive tracer Technetiu

198 with type 2 diabetes, we also observed that intravenous infusion of the same n-apo AI (CSL111, 80 mg

199 to discrete pulses of activity revealed that intravenous infusion of the synthetic mixed glucocortico

200 CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of CD133-positive ha

201 monary hypertension was induced in 8 pigs by intravenous infusion of thromboxane A2 analogue.

202 Evaluate the safety and efficacy of the intravenous infusion of UC-MSC in patients with chronic

203 Intravenous infusion of UC-MSC was safe in this group of

204 on fraction, no clinical trial has evaluated intravenous infusion of UC-MSCs in these patients.

205 urs following no infusion (controls; n=6) or intravenous infusion of ultrasmall superparamagnetic par

206 diac arrest undergoing CPR to either a rapid intravenous infusion of up to 2 L of cold saline or stan

207 A single intravenous infusion of vector in all 10 patients with s

208 Patients were randomly assigned to receive intravenous infusion of vitamin C (50 mg/kg in dextrose

209 Intravenous infusion of WST11 (4 mg per kilogram of body

210 phthalmologist-confirmed AAU occurring after intravenous infusion of zoledronate (5 mg).

211 Intravenous infusion of zoledronate 5 mg or placebo.

212 who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placeb

213 A single 5 mg intravenous infusion of zoledronic acid is non-inferior,

214 Intravenous infusions of (13)C-labelled nutrients reveal

215 We compared the effects of intravenous infusions of 0.9% saline ([Cl] 154 mmol/L) a

216 or greater were randomized to 3 once-monthly intravenous infusions of 10 mg/kg GSK679586 (n = 99) or

217 nteractive voice response system, to receive intravenous infusions of 10 mg/kg ipilimumab or placebo

218 to 400 m on 6 MWT, were randomized to weekly intravenous infusions of 30 or 50 mg/kg/wk eteplirsen or

219 cular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m(2) CT-P10 or rituximab

220 onditions and during 4 postprandial hours by intravenous infusions of [3,3,3-(2)H3]-leucine and [ring

221 ate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH(2) (800 pmol/kg/

222 tients with AATD were treated with 12 weekly intravenous infusions of AAT augmentation therapy before

223 andomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicemine 50 mg, la

224 th prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Abeta

225 t desmopressin (1 nmol.kg(-1)) or continuous intravenous infusions of arginine vasopressin (3 pmol.kg

226 efore starting treatment and after 12 weekly intravenous infusions of AVI-4658.

227 atomegaly also occurs when animals are given intravenous infusions of bacterial lipopolysaccharide (L

228 ) patients with cancer who were treated with intravenous infusions of bisphosphonates between January

229 rrent hemophilia treatment involves frequent intravenous infusions of clotting factors, which is asso

230 Rats were trained to lever press for intravenous infusions of cocaine before extinction.

231 of 179 (44-384) mL/min/1.73m2, who received intravenous infusions of colistimethate each 8 hours.

232 All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a d

233 eal was used to measure energy intake during intravenous infusions of either PYY(3-36) or oxyntomodul

234 ntuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24

235 intravenous infusions of placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg

236 in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.

237 Patients were assigned randomly to receive intravenous infusions of infliximab 5 mg/kg at weeks 0,

238 lesions report panic anxiety in response to intravenous infusions of isoproterenol, a beta-adrenergi

239 ) patients were randomized to receive either intravenous infusions of LOLA (n = 98), 30 g daily, or p

240 Our recent work has shown that intravenous infusions of mesenchymal-derived extracellul

241 twice daily on days 1-10 of 28-day cycles); intravenous infusions of mitoxantrone (8 mg/m(2) per day

242 , experimentally induced asthma received six intravenous infusions of MSCs (0.36-2.5 x 10E7 MSCs/infu

243 Participants received 30 minute intravenous infusions of NKB and vehicle in random order

244 anges in venous oxygenation before and after intravenous infusions of placebo and psilocybin.

245 d by study centre to standard care plus 48-h intravenous infusions of placebo or serelaxin (30 mug/kg

246 or > or = 4 weeks were randomized to receive intravenous infusions of placebo plus MTX or intravenous

247 Patients were assigned to receive intravenous infusions of RRx-001 at increasing doses (10

248 uropathic pain)-and a control group received intravenous infusions of saline in an initial session an

249 hyroid eye disease in a 1:1 ratio to receive intravenous infusions of the IGF-IR inhibitor teprotumum

250 inuation of ART, participants received eight intravenous infusions of UB-421, at a dose of either 10

251 lve healthy adult male subjects received 1-L intravenous infusions of Voluven or PVR over 30 minutes

252 e or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of bo

253 However, catheter-based delivery, but not intravenous infusion, of LNA-92a significantly (P<0.05)

254 Rituximab was given at 375 mg/m(2) as an intravenous infusion on day 1 of each cycle.

255 1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200

256 a fixed dose of 15 000 IU/m(2) bleomycin by intravenous infusion on day 4.

257 56 mg/m(2) thereafter) was given as a 30-min intravenous infusion on days 1, 2, 8, 9, 15, and 16 of 2

258 eceived romidepsin at 14 mg/m(2) as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days.

259 d induction chemotherapy (daunorubicin bolus intravenous infusion on days 1-3 [90 mg/m(2) for patient

260 5-Fluorouracil (800 mg/m(2) intravenous infusion on days 1-5) was permitted in patie

261 aged >60 years], plus cytarabine continuous intravenous infusion on days 1-7 [100 mg/m(2)]), with el

262 les with loading doses of 10 mg/kg by 60 min intravenous infusions on days 1, 3, and 5 in the first w

263 days) (n = 551) or gemcitabine (1000 mg/m(2) intravenous infusion once a week for 3 of every 4 weeks)

264 rmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d.

265 o receive 0.3 mg/kg patisiran or placebo via intravenous infusion once every 3 weeks for 18 months.

266 APR-246 was administered as a 2-hour intravenous infusion once per day for 4 consecutive days

267 rs were treated with cixutumumab as a 1-hour intravenous infusion once per week.

268 near-constant obsessions received two 40-min intravenous infusions, one of saline and one of ketamine

269 lipressin has been used either as continuous intravenous infusion or as intravenous boluses.

270 ow oral availability and requires continuous intravenous infusion or multiple gram doses to ensure su

271 s infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1.3 mg/m(2); intrav

272 ntravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/

273 ays and 28 mug/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to f

274 m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15

275 e plus 16 cycles of 7.5 mg/kg bevacizumab by intravenous infusion over 90 min on day 1 of each cycle.

276 mg) or placebo was administered as a single intravenous infusion over a 1-hour period.

277 receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 week

278 lve healthy adult male subjects received 2-L intravenous infusions over 1 hour of 0.9% saline or Plas

279 (HR: 3.4), low CIT (HR: 3.3), and number of intravenous infusions per week (HR: 1.4).

280 ts) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care includi

281 d through systemic administration (typically intravenous infusion), precluding the feasible dosing of

282 n dose levels of IPH4102, administered as an intravenous infusion, ranging from 0.0001 mg/kg to 10 mg

283 s compare the efficacy of different forms of intravenous infusion sedation for critically ill patient

284 f mechanically ventilated patients receiving intravenous infusion sedation has increased over time.

285 We sought to describe current use of intravenous infusion sedation in mechanically ventilated

286 Imetelstat was administered as a 2-hour intravenous infusion (starting dose, 9.4 mg per kilogram

287 In a double-blind, placebo-controlled intravenous infusion study of ketamine, we measured glut

288 ndomly assigned to receive either continuous intravenous infusion (TERLI-INF group) at the initial do

289 on of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD w

290 time to FFR was 100 +/- 27 s for continuous intravenous infusion versus 23 +/- 14 s for intracoronar

291 administration of terlipressin as continuous intravenous infusion versus intravenous boluses in the t

292 Dexamethasone (20 mg oral or intravenous infusion) was given on days 1, 2, 8, 9, 15,

293 eceived gemcitabine 1000 mg/m(2) as a 30-min intravenous infusion, weekly, for 7 weeks followed by a

294 Three 52-min intravenous infusions were administered: ketamine (.41 m

295 In study B, intravenous infusions were identical, but an oral mixed-

296 as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion dem

297 Intravenous infusion with either 5 mg of zoledronic acid

298 Intravenous infusion with IS confirmed the superfusion r

299 Forty-three patients were treated by intravenous infusion with MK-8776 at seven dose levels r

300 each diet, subjects cycled for 60 min after intravenous infusion with saline (CD and HFD) or dichlor